Clinical trials: Liver Transplantation
Chronic Hepatitis B
Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant
The objective of this 96-week study was to evaluate the safety and antiviral efficacy of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, coformulated; Truvada®) with or without hepatitis B immunoglobulin (HBIg) in…
- Trial name
- NCT00507689
- Testing
- FTC/TDF, Hepatitis B Immunoglobulin (HBIg)
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Liver Transplant; Complications
Study to Compare the Incidence of Biliary Complications After Liver Transplantation
A randomized prospective study will be conducted of patients at Vanderbilt University Medical Center who undergo liver transplantation from March 2014 until approximately 120 patients are randomized.
- Trial name
- NCT03165916
- Testing
- Bard 5 Fr diameter feeding tube
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Vanderbilt University Medical Center
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Liver Transplantation
RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency
The purpose of the study is to assess the effect of everolimus initiation together with reduction or discontinuation of calcineurin inhibitor (CNI) on renal function in maintenance liver transplant recipients with CNI-related…
- Trial name
- NCT00267189
- Testing
- Everolimus, Calcineurin inhibitors (CNI), Mycophenolate acid (MPA)/ Azathioprine (AZA)
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 145 people
- Sponsor
- Novartis Pharmaceuticals
Asses Immunosuppression Modulation on Renal Recovery Post LT
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard…
- Trial name
- NCT04104438
- Testing
- Basiliximab 20 MG
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Fady M Kaldas, M.D., F.A.C.S.
Respiratory Failure, Hepatitis C
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 8 weeks of commercially available DAA therapy to prevent…
- Trial name
- NCT03625687
- Testing
- Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
Cancer, Cholangiocarcinoma
Liver Transplantation for Cholangiocarcinoma
Today, available therapies for hilar cholangiocarcinomas (CCA) are not satisfactory. Although these tumors are rare, their study is important because of the high death rates in afflicted patients, rivaling that of pancreatic…
- Conditions
- Cancer, Cholangiocarcinoma, Liver
- Trial name
- NCT00708877
- Testing
- Liver Transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Liver Transplantation
A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients
A study to assess the pharmacokinetics, safety and effectiveness of tacrolimus in stable pediatric liver transplant patients converted from a Prograf® based immunosuppression regimen to a modified release tacrolimus based…
- Trial name
- NCT00282256
- Testing
- tacrolimus modified release (MR), tacrolimus
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Astellas Pharma Inc
Chronic Hepatitis C, HCV
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C…
- Conditions
- Chronic Hepatitis C, HCV, Hepatitis C Virus
- Trial name
- NCT02692703
- Testing
- glecaprevir/pibrentasvir
- Volunteers
- 100 people
- Sponsor
- AbbVie
Bile Leak
Plastic vs. Fully Covered Self Expanding Stents (FCSEMS) for Treatment of Anastomotic Bile Leaks
Standard endoscopic management for anastomotic bile leaks following OLT has been endoscopic retrograde cholangiopancreatography (ERCP) with placement of a temporary plastic biliary endoprosthesis (stent) across the site of…
- Trial name
- NCT03333382
- Testing
- Plastic biliary stent, FCSEMS
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Vanderbilt University Medical Center
Immunosuppression
A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients
The objective of this study is to compare the safety and efficacy of Myfortic with CellCept in liver transplant patients. Myfortic and CellCept are both immunosuppressive (anti-rejection) drugs.
- Trial name
- NCT00336817
- Testing
- Myfortic, CellCept
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Transplant
Improving Medication Adherence in Adolescents Who Had a Liver Transplant
The study's aim is to test a tailored telemetric intervention to reduce rejection incidence by improving medication adherence in a group of adolescent liver transplant recipients identified as nonadherent by a marker (the…
- Trial name
- iMALT (NCT03691220)
- Testing
- Telemetric Intervention
- Where
- 13 sites in United States, Canada
- Volunteers
- 148 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatocellular Carcinoma, HCC
Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
This study will compare stereotactic body radiation therapy (SBRT) to trans-arterial chemoembolization (TACE) as a bridging strategy for patients with HCC undergoing liver transplantation.
- Trial name
- SBRTvsTACE (NCT03960008)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
- Where
- 5 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Lahey Clinic
Cytomegalovirus (CMV) Infections Among Children and Adult Liver Transplantation Patients in China
A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China
The goal of this observational study is to learn about cytomegalovirus disease epidemiology in pediatric and adult liver transplant recipients in China.
- Trial name
- NCT05958186
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Lin Zhong
Liver Failure
Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients
The purpose of this study is to demonstrate the pharmacokinetics (PK, measuring the amount of medication in blood samples) and safety of a new medicine, LCP-Tacro™ tablets, and Prograf® capsules, a drug commonly taken by…
- Trial name
- NCT00772148
- Testing
- LCP -Tacro, Prograf
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Veloxis Pharmaceuticals
Liver Transplantation
Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation
This is an investigator initiated study at the University of California, Los Angeles (UCLA) funded by Novartis looking at using a combination of immunosuppressive drugs in liver transplant patients that are at risk of developing…
- Trial name
- NCT02123108
- Testing
- Basiliximab, Tacrolimus, Mycophenolic Acid
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of California, Los Angeles
Cervical Cancer, Hpv
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
The purpose of the study is to understand if children with liver and kidney transplants develop the antibodies from the Gardasil vaccine.
- Conditions
- Cervical Cancer, Hpv, Warts
- Trial name
- NCT01101750
- Testing
- Quadrivalent HPV for types 6, 11, 16 and 18
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Medstar Health Research Institute
Liver Transplantation, Kidney Transplantation
Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
We hypothesize that delayed graft function and ITBS events may be related to small blood clots (microthrombi) that collect in the kidneys and liver after cardiac death.
- Trial name
- NCT01197573
- Testing
- rTPA Treatment, No TPA Treatment
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- The Cleveland Clinic
Postoperative Graft Function
Hepatic Vein Flow During Orthotopic Liver Transplantation as Predictive Factor for Postoperative Graft Function
Hepatic vein flow (HVF) assessment using transesophageal echocardiography (TEE) has a potential to predict postoperative graft function in orthotopic liver transplant (OLT).
- Trial name
- NCT03814031
- Testing
- NO internvention
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Henry Ford Health System